KALA BIO, Inc. Common Stock

KALANASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
2.06 USD
↘ 0.17 (7.62%)AT CLOSE (11:59 AM EDT)
2.16
↗ 0.10 (4.81%)
POST MARKET (AS OF 07:48 PM EDT)
Post Market
AS OF 07:48 PM EDT
2.16
↗ 0.10 (4.81%)
🔴Market: CLOSED
Open?$2.25
High?$2.30
Low?$2.03
Prev. Close?$2.23
Volume?127.6K
Avg. Volume?1.7M
VWAP?$2.13
Rel. Volume?0.08x
Bid / Ask
Bid?$2.12 × 200
Ask?$2.44 × 1.4K
Spread?$0.32
Midpoint?$2.28
Valuation & Ratios
Market Cap?38.3M
Shares Out?18.6M
Float?796.5M
Float %?83.4%
P/E Ratio?N/A
P/B Ratio?3.56
EPS?-$1.06
Dividend?0.00%
Ex-Dividend?N/A

KALA is currently priced at $2.06. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. KALA is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Themes
Biotech - Drug Development›Rare Disease Therapeutics
Employees
6
Market Cap
41.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.kalarx.com
Listed
2017-07-20
Address
1167 MASSACHUSETTS AVENUE
ARLINGTON, MA 02476
Phone: 781-996-5252
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
80
Piotroski F-Score?0/9Weak
Altman Z-Score?-70.26Distress
Confidence?40%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.01%Low
Short Interest?42.6K
Days to Cover?1.0
Free Float796.5M
Avg Daily Volume90.5K
Settlement Date2026-05-15
Financial Health
Current Ratio?7.91Strong
Quick Ratio?7.91Strong
Cash Ratio?1.13Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
48
3.56FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-182.6%WEAK▾
ROA?
S&P
3
-159.6%WEAK▾
Cash Flow & Enterprise
FCF?$-26077000
Enterprise Value?$36.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist